Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 2, 2001, Pages 113-119

  Guerra, P ^a   Frias, J ^a   Ruiz, B ^a   Soto, A ^a   Carcas, A ^a   Govantes, C ^b   Montuenga, C ^b   Fernandez A ^c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Laboratorios Normon   (Spain)

^c Universidad Autónoma de Madrid ^*

Author keywords

Active metabolites bioequivalence; Allopurinol; Drug bioequivalence; Oxypurinol

Indexed keywords

ALLOPURINOL; OXIPURINOL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN;

ADULT; ALLOPURINOL; AREA UNDER CURVE; CROSS-OVER STUDIES; ENZYME INHIBITORS; HUMANS; MALE; OXYPURINOL; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0035063293     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00329.x     Document Type: Article

References (26)

1. Clinical pharmacokinetics of allopurinol
2. Crystal-associated rheumatic disease. Current management considerations
3. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol
4. The role of metabolites in bioequivalence assessment. 1. Linear pharmacokinetics without first-pass effect
5. Bioequivalence of allopurinol preparations: To be assessed by the parent drug or the active metabolite?
6. Allopurinol. A comparative study of the bioavailability and effect on plasma uric acid of two products in tablet form
7. Bioequivalence of allopurinol-containing tablet preparations
8. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects
9. Sample sizes for bioequivalence studies
10. A comparison of the two onesided test procedure and the power approach for assessing the equivalence of average bioavailability
11. A distribution-free procedure for the statistical analysis of bioequivalence studies
12. On the assessment of bioequivalence in a two-period cross-over design
13. International harmonization of regulatory bioequivalence requirements
14. Allopurinol kinetics in humans as a means to asses liver function, evaluation of an allopurinol loading test
15. Liver function assessment by drug metabolism
16. Disposition and uric acid lowering effect of oxipurinol. Comparison of different oxipurinol formulations and allopurinol in healthy individuals
17. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients. Therapeutic equivalence to allopurinol
18. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy
19. Pharmacodynamics of oxypurunol after administration of allopurinol to healthy subjects
20. The bioavailability of two commercial preparations of allopurinol tablets